EXACT THERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.8 NOK | -2.86% |
|
-2.86% | -43.33% |
| Sales 2022 | 455K 41.54K | Sales 2023 | 4.46K 407.41 | Capitalization | 385M 35.18M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -3.66M | Net income 2023 | -48M -4.39M | EV / Sales 2022 | 643 x |
| Net cash position 2022 | 67.7M 6.19M | Net cash position 2023 | 45.23M 4.13M | EV / Sales 2023 | 76,207 x |
| P/E ratio 2022 |
-8.96
x | P/E ratio 2023 |
-7.95
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.72% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.86% | ||
| 1 week | -2.86% | ||
| Current month | +13.33% | ||
| 1 month | +19.30% | ||
| 3 months | -43.33% | ||
| 6 months | -48.09% | ||
| Current year | -43.33% |
1 week
6.80
7.00
1 month
5.207.40
Current year
4.8012.00
1 year
4.8020.00
3 years
4.8028.60
5 years
4.8053.59
10 years
4.8053.59
| Managers | Title | Age | Since |
|---|---|---|---|
Svein Kvåle
FOU | Founder | - | 11-12-31 |
Per Walday
CEO | Chief Executive Officer | 64 | 22-03-27 |
John Edminson
DFI | Director of Finance/CFO | - | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Castell
BRD | Director/Board Member | 76 | 18-06-21 |
| Director/Board Member | 57 | - | |
| Director/Board Member | 53 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 6.8 | -2.86% | 700 |
| 24-04-24 | 7 | 0.00% | 0 |
| 24-04-23 | 7 | 0.00% | 0 |
| 24-04-22 | 7 | 0.00% | 0 |
| 24-04-19 | 7 | 0.00% | 3,500 |
Real-time Oslo Bors, April 25, 2024 at 03:36 am EDT
More quotes
Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.
Calendar
2024-06-06
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -43.33% | 20.42M | |
| +4.09% | 43.84B | |
| +46.90% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- EXTX Stock
